ArticleGastroenterology research2025
The Impact of Chronic Pancreatitis Etiology on Clinical Outcomes: A Population-Based Propensity-Matched Analysis.
Article in Gastroenterology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic pancreatitis (CP) is a complex disease with various underlying etiologies, including alcohol consumption, smoking, autoimmune disorders, genetic predispositions, and other less common causes. Despite extensive research, the impact of these different etiologies on disease progression, complication rates, and long-term outcomes remains insufficiently understood. In particular, the distinction between alcohol-related chronic pancreatitis (ARCP) and non-alcohol-related chronic pancreatitis (NARCP) is not well established in terms of prognosis and therapeutic needs. Methods: We conducted a retrospective cohort study utilizing the TriNetX US Collaborative Network to compare baseline characteristics and clinical outcomes of ARCP versus NARCP. Propensity score matching (PSM) was applied to balance baseline characteristics between both cohorts. Primary outcome was mortality, while secondary outcomes included exocrine pancreatic insufficiency (EPI), pseudocyst formation, development of diabetes and pancreatic cancer, and need for endoscopic retrograde cholangiopancreatography (ERCP) and celiac plexus injection. Results: A total of 203,432 patients with CP were identified, including 11,696 ARCP and 200,560 with NARCP. After PSM (11,678 per group), ARCP was associated with significantly lower rates of mortality (13.0% vs. 16.2%; risk ratio (RR) 0.80), diabetes (22.9% vs. 35.8%; RR 0.64), exocrine pancreatic insufficiency (2.0% vs. 6.1%; RR 0.32), pancreatic cancer (1.1% vs. 8.4%; RR 0.14), and pseudocyst formation (7.1% vs. 9.7%; RR 0.73) compared to NARCP (all P < 0.001). ARCP patients also had lower rates of celiac plexus injection (0.1% vs. 0.8%; RR 0.12) and ERCP (2.3% vs. 10.2%; RR 0.23) (both P < 0.001). Conclusion: In this large, retrospective cohort study, patients with ARCP demonstrated lower rates of mortality, complications, and need for interventions compared to those with NARCP. These findings highlight potential differences in disease progression and clinical management between ARCP and NARCP. Further studies are needed to elucidate underlying mechanisms contributing to these disparities and to refine patient-specific treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.